Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TVRD Tvardi Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: TVRD
Price (delayed)
$25.61
Market cap
$117.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.53
Enterprise value
$123.68M
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in
Highlights
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Tvardi Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Tvardi Therapeutics's equity has plunged by 108% YoY
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of TVRD
Market
Valuations
Earnings
Shares outstanding
4.57M
Market cap
$117.13M
Enterprise value
$123.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
16.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.33
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
EBIT
-$62.79M
EBITDA
-$61.83M
Free cash flow
-$61.96M
Per share
Balance sheet
Liquidity
EPS
-$15.53
EPS diluted
-$15.53
Free cash flow per share
-$13.58
Book value per share
-$1
Revenue per share
$1.56
TBVPS
$9.61
Total assets
$43.83M
Total liabilities
$48.42M
Debt
$44.45M
Equity
-$4.59M
Working capital
$39.86M
Debt to equity
-9.68
Current ratio
11.03
Quick ratio
10.67
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-866.4%
Gross margin
91.3%
Net margin
-993%
Operating margin
-919.4%
Return on assets
-110%
Return on equity
-755.6%
Return on invested capital
-112.6%
Return on capital employed
-157.6%
Return on sales
-879.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVRD stock price
How has the Tvardi Therapeutics stock price performed over time
Intraday
-1.69%
1 week
-4.19%
1 month
422.65%
1 year
180.81%
YTD
318.46%
QTD
405.13%
Financial performance
How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
Gross margin
91.3%
Net margin
-993%
TVRD's net margin has dropped by 76% year-on-year but it is up by 10% since the previous quarter
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Tvardi Therapeutics's operating margin has plunged by 59% YoY but it has increased by 14% from the previous quarter
TVRD's gross profit has plunged by 56% YoY and by 13% from the previous quarter
Price vs fundamentals
How does TVRD's price correlate with its fundamentals
Growth
What is Tvardi Therapeutics's growth rate over time
Valuation
What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
16.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.33
Tvardi Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Tvardi Therapeutics's equity has plunged by 108% YoY
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
TVRD's P/S is 57% above its 5-year quarterly average of 10.4
Efficiency
How efficient is Tvardi Therapeutics business performance
Tvardi Therapeutics's return on equity has shrunk by 96% QoQ
Tvardi Therapeutics's ROS has plunged by 56% YoY but it has increased by 14% from the previous quarter
TVRD's return on invested capital is up by 36% year-on-year and by 15% since the previous quarter
TVRD's ROA is down by 23% YoY but it is up by 2.2% QoQ
Dividends
What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVRD.
Financial health
How did Tvardi Therapeutics financials performed over time
The total assets is 9% less than the total liabilities
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Tvardi Therapeutics's current ratio has soared by 143% YoY and by 131% from the previous quarter
The company's debt to equity has shrunk by 116% QoQ
Tvardi Therapeutics's equity has plunged by 108% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.